Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

Exclusion Criteria

• •patients with other malignancies, except non melanoma of the skin, who have had any evidence of cancer within the last 5 years
• •patients with psychiatric illness or other concurrent severe co-morbid medical condition that would preclude study completion
• •known uncontrolled existing coagulopathy
• •patients with a history of severe hypersensitivity reaction to docetaxel, medications formulated with polysorbate 80 or 5-fluorouracil
• •use of other investigational agents in the last 28 days
• •pregnant or lactating women
• •patients who are known HIV positive
• •patients with life expectancy of less than 3 months
• •sexually active patients unwilling to practice reliable contraception during the study